Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Australian (ASX) Biotech Industry Analysis

UpdatedApr 14, 2026
DataAggregated Company Financials
Companies32
  • 7D0.04%
  • 3M-19.1%
  • 1Y-40.0%
  • YTDn/a

Over the last 7 days, the Biotech industry has remained flat, although notably Telix Pharmaceuticals gained 22%. As for the longer term, the industry has declined 38% in the last year. As for the next few years, earnings are expected to grow by 31% per annum.

Industry Valuation and Performance

Has the Australian Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 14 Apr 2026AU$77.7bAU$23.4bAU$1.4b23.6x54.5x3.3x
Thu, 12 Mar 2026AU$79.9bAU$23.0bAU$1.4b25.3x57.2x3.5x
Sat, 07 Feb 2026AU$97.6bAU$23.5bAU$3.8b20.2x25.5x4.1x
Mon, 05 Jan 2026AU$95.3bAU$24.6bAU$4.0b18.5x23.8x3.9x
Wed, 03 Dec 2025AU$101.3bAU$25.1bAU$4.1b19.3x24.6x4x
Fri, 31 Oct 2025AU$99.9bAU$25.1bAU$4.1b19x24.3x4x
Sun, 28 Sep 2025AU$106.1bAU$25.1bAU$4.1b20.5x25.8x4.2x
Tue, 26 Aug 2025AU$117.9bAU$25.3bAU$4.2b37.2x27.9x4.7x
Thu, 24 Jul 2025AU$142.5bAU$24.2bAU$3.8b41.3x37.4x5.9x
Sat, 21 Jun 2025AU$130.0bAU$24.5bAU$3.9b20x33.6x5.3x
Mon, 19 May 2025AU$131.5bAU$24.8bAU$3.9b20.6x33.5x5.3x
Wed, 16 Apr 2025AU$132.2bAU$25.0bAU$4.0b20.6x33.4x5.3x
Fri, 14 Mar 2025AU$134.9bAU$25.3bAU$4.0b21.2x33.7x5.3x
Sun, 09 Feb 2025AU$148.1bAU$24.5bAU$3.7b24.2x40.4x6x
Tue, 07 Jan 2025AU$153.1bAU$24.5bAU$3.7b24.6x41.9x6.3x
Thu, 05 Dec 2024AU$151.3bAU$24.0bAU$3.6b25.7x42.3x6.3x
Sat, 02 Nov 2024AU$148.7bAU$23.4bAU$3.5b26.6x42.7x6.3x
Mon, 30 Sep 2024AU$149.9bAU$22.3bAU$3.3b28.1x45.6x6.7x
Wed, 28 Aug 2024AU$160.2bAU$22.8bAU$3.5b30.5x46.4x7x
Fri, 26 Jul 2024AU$159.1bAU$22.5bAU$3.3b32x48x7.1x
Sun, 23 Jun 2024AU$153.1bAU$22.2bAU$3.3b31.8x47x6.9x
Tue, 21 May 2024AU$144.2bAU$22.0bAU$3.2b31x44.9x6.6x
Thu, 18 Apr 2024AU$141.3bAU$22.9bAU$3.4b29.7x42x6.2x
Sat, 16 Mar 2024AU$143.3bAU$22.4bAU$3.3b30.5x43.8x6.4x
Mon, 12 Feb 2024AU$154.9bAU$21.0bAU$2.9b35x54.2x7.4x
Wed, 10 Jan 2024AU$147.3bAU$20.5bAU$2.7b34.6x54.3x7.2x
Fri, 08 Dec 2023AU$135.7bAU$20.9bAU$2.8b34.1x48.9x6.5x
Sun, 05 Nov 2023AU$124.1bAU$21.1bAU$2.8b30x44.2x5.9x
Tue, 03 Oct 2023AU$126.5bAU$21.5bAU$2.8b29.2x44.9x5.9x
Thu, 31 Aug 2023AU$139.2bAU$21.3bAU$2.6b35.3x54x6.5x
Sat, 29 Jul 2023AU$137.8bAU$18.1bAU$2.3b37.4x59x7.6x
Mon, 26 Jun 2023AU$145.0bAU$18.0bAU$2.3b37.8x62.4x8.1x
Wed, 24 May 2023AU$158.3bAU$18.2bAU$2.3b41x67.5x8.7x
Fri, 21 Apr 2023AU$153.5bAU$17.8bAU$2.3b42x66.8x8.6x
Price to Earnings Ratio

66.8x


Total Market Cap: AU$153.5bTotal Earnings: AU$2.3bTotal Revenue: AU$17.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Australian Biotech Industry Price to Earnings3Y Average 43.3x202420252026
Current Industry PE
  • Investors are optimistic on the Australian Biotechnology industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 55.3x which is higher than its 3-year average PE of 43.3x.
  • The 3-year average PS ratio of 6.0x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have declined 15% per year over the last three years.
  • Meanwhile revenues for these companies have grown 9.1% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Australian Biotech compare with similar industries?

AU Market3.84%
Healthcare1.08%
Biotech0.044%
Biotech0.044%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TLX Telix PharmaceuticalsAU$15.4513.8%
+AU$633.7m		-41.3%PS4.6x
PYC PYC TherapeuticsAU$1.158.0%
+AU$83.6m		6.5%PS55x
RAC Racura OncologyAU$2.8110.6%
+AU$49.2m		181.0%PS147.3x
TTX TetratherixAU$5.2222.0%
+AU$47.7m		n/aPS132.6x
DXB DimerixAU$0.3818.8%
+AU$36.0m		-8.4%PS30.8x

Latest News

PAR
AU$0.22
Paradigm Biopharmaceuticals
7D
-12.0%
1Y
-31.3%
OCC
AU$0.87
Orthocell
7D
14.5%
1Y
-40.0%
TLX
AU$15.45
Telix Pharmaceuticals
7D
13.8%
1Y
-41.3%
ATH
AU$0.009
Alterity Therapeutics
7D
12.5%
1Y
12.5%
CSL
AU$138.08
CSL
7D
-1.6%
1Y
-43.4%

CSL: Manufacturing Expansion And CEO Transition Will Support Future Share Recovery

Analysts have slightly increased CSL's fair value estimate to A$208.11, citing modest adjustments to the discount rate, revenue growth, profit margin and a higher assumed future P/E multiple as they reassess the stock following recent rating changes. Analyst Commentary Recent rating actions around CSL highlight a split in views on how much investors should pay for the stock at this stage, which feeds directly into the updated fair value estimate of A$208.11.
ARX
AU$0.51
Aroa Biosurgery
7D
-7.3%
1Y
22.9%

Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time

Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?
RAC
AU$2.81
Racura Oncology
7D
10.6%
1Y
181.0%
ACW
AU$0.038
Actinogen Medical
7D
-5.0%
1Y
40.7%
PYC
AU$1.15
PYC Therapeutics
7D
8.0%
1Y
6.5%
IMM
AU$0.039
Immutep
7D
-11.4%
1Y
-83.0%
TTX
AU$5.22
Tetratherix
7D
22.0%
1Y
n/a
MSB
AU$2.01
Mesoblast
7D
1.3%
1Y
18.2%
IMU
AU$0.14
Imugene
7D
-3.4%
1Y
-85.3%
IMC
AU$0.027
Immuron
7D
-6.9%
1Y
-58.5%
DXB
AU$0.38
Dimerix
7D
18.8%
1Y
-8.4%
BDX
AU$0.086
BCAL Diagnostics
7D
-4.4%
1Y
-8.5%